Uro-Oncology | Urothelial Carcinoma · Robotic Surgery | Kidney Transplant Surgeon | AI in Uro-Oncology | EAU-YAU | Clinical Trials | Hospital Ramón y Cajal
Joined September 2009
- Tweets 1,696
- Following 836
- Followers 1,024
- Likes 2,298
79 Photos and videos
Jose Daniel Subiela retweeted
🥇Happy to have received the prize for the most cited article for the Resident's Section in 2025 in @actasurologicas @InfoAeu #AEU26, brilliantly written by Silvia Juste
🔗Read it here: t.ly/8VmM-
@GUOaeu @RodriguezFaba @cgdelcanizo @JGomezRivas @EnguitaCarmen @albertobudiaalb @CoralManso @Urologia12 @ResidentesAEU @H12Octubre @CAU_URO @ResidentesCAU
8
24
918
Jose Daniel Subiela retweeted
Jun 11
🚀 Delighted to be attending the Inaugural Ceremony of the 89th National Congress of Urology 🇪🇸
A great opportunity to learn, share experiences, and strengthen multidisciplinary collaboration in the care of our patients. 🤝🔬
Looking forward to an inspiring meeting. @InfoAeu
5
12
589
Jose Daniel Subiela retweeted
Our News systematic review @FPuigvert highlights that pathological response after neoadjuvant therapy may provide valuable prognostic information in metastatic RCC, often beyond what radiological assessment alone can capture.
Read here:
eu-central-1.protection.soph…
6
17
1,324
Jose Daniel Subiela retweeted
May 28
👏👏👏 Great job my friend!!
👉 Always working together in a multidisciplinary team!! This the right way to go!! long road to get there! 👉
: the idea➡️ proposal➡️ funding➡️ recruitment➡️analysis / publication
@ASCO @UroTarget @OncoAlert @H12Octubre
🤩Glad to share the final results of our #BladderGATE trial published at @OncJournal
👓Read it here: t.ly/tECGh
🙏Deep gratitude to all @Urologia12 MDT team: @cdanicas @g_develasco @cgdelcanizo @MarioHArroyo @MartaDueas4 @H12Octubre @SaludMadrid
@GuardConsortium @GUOaeu @ROC_Urologia @UAI_imas12 @InfoAeu @CANVES_ES @ApicesSpain @F_OncoSur @docjavip @dralvaropinto @drenriquegrande @BenjaminPradere @MRoupret @evanguelosx @spsutkaMD @UroDocAsh @A_Carrion_Puig @ADominguez_Uro @dr_flozano @DominguezEscrig @josedsh @RodriguezFaba @paolo_gontero @MariaJRibal @JGomezRivas @tompowles1 @Uro_Oncologist @mjuanfi81
2
6
11
1,686
Jose Daniel Subiela retweeted
Fully agree. @josedsh @FVillacampaCUN and I ran those numbers
NNT and NNH summarize it pretty well
For Sasanlimab the NNT is 14,
while the NNH is 4
For Durvalumab
the NNT is 23 and the NNH is 6
Statistically more likely to harm (grade 3 or higher) than benefit unelected pts
1
2
3
209
Jose Daniel Subiela retweeted
🚨A lot of new options for #BCGunresponsive NMIBC, but no direct comparisons
🤼We've tried to do some work on this, along with my friend @siadaneshmand and others
📖You can read it here @JUrology @AmerUrological @JUOpenPlus: t.ly/UxDFA
👀And much more to come!!!
11
19
938
Jose Daniel Subiela retweeted
🤩Glad to share the final results of our #BladderGATE trial published at @OncJournal
👓Read it here: t.ly/tECGh
🙏Deep gratitude to all @Urologia12 MDT team: @cdanicas @g_develasco @cgdelcanizo @MarioHArroyo @MartaDueas4 @H12Octubre @SaludMadrid
@GuardConsortium @GUOaeu @ROC_Urologia @UAI_imas12 @InfoAeu @CANVES_ES @ApicesSpain @F_OncoSur @docjavip @dralvaropinto @drenriquegrande @BenjaminPradere @MRoupret @evanguelosx @spsutkaMD @UroDocAsh @A_Carrion_Puig @ADominguez_Uro @dr_flozano @DominguezEscrig @josedsh @RodriguezFaba @paolo_gontero @MariaJRibal @JGomezRivas @tompowles1 @Uro_Oncologist @mjuanfi81
3
15
38
3,467
Jose Daniel Subiela retweeted
📝Awesome summary by @chavarriagaj @urotoday on our #AUA26 @IBCG_BladderCA @AmerUrological session last Sunday: t.ly/BLs2w
😅Really enjoyed discussing with @shilpaonc & @AndreaNecchi
💎Brilliantly led by @spsutkaMD & @UroDocAsh
@CAU_URO @InfoAeu @GuardConsortium @H12Octubre @Urologia12 @ROC_Urologia @CANVES_ES @BladderCancerUS @WorldBladderCan
7
16
1,031
May 18
🧵 Out now in European Urology — our editorial on dual-biomarker monitoring (ctDNA utDNA) for bladder-sparing therapy in MIBC.
4 independent 2026 trials converge: plasma ctDNA & utDNA carry complementary, non-overlapping information. Neither alone is sufficient.
1
6
16
589
May 18
5 scenarios on the ctDNA × utDNA grid (see figure):
1️⃣ −/− cCR: → preserve 2️⃣ utDNA cCR: → surveil 3️⃣ no-cCR/ctDNA−: still curable locally 4️⃣ ctDNA only: escalate systemic, not cystectomy 5️⃣ / no-cCR: change Tx
1
76
May 18
Bottom line: dual-compartment liquid biopsy = rational framework for future bladder-sparing trials.
📖 Free access (50 days): authors.elsevier.com/a/1n6Ng…
@Daniel_Urologia @Renate_Pichler @BenjaminPradere #PietroScilipoti
55
Jose Daniel Subiela retweeted
🚨SAVE THE DATE! 9th June @H12Octubre
👩🏫MASTERCLASS IN BLADDER CANCER 2026, register here: t.ly/oq7v8
🔝Program with TOP speakers
@cdanicas @PazAresLab @docjavip @MartaDueas4 @AlvarezMa89031 @DominguezEscrig @RodriguezFaba @evanguelosx @MarioHArroyo @elenasefer @FaltasLab @LAUrology_NL @dr_flozano @A_Carrion_Puig @josedsh @dralvaropinto @cgdelcanizo @g_develasco @mjuanfi81 @drenriquegrande @giannatempopatr @nachoduranm @tactics_md @H12Octubre @InfoAeu @ResidentesAEU @Urologia12
17
36
1,675
1/ 🚨 New review:
“Perioperative Management of UTUC: Current Evidence & Future Directions”
Most of what we do in UTUC is still extrapolated from bladder cancer. We tried to map where we stand — and where the field is heading.
🔗 DOI: 10.1159/000551611
🧵⬇️
1
1
7
502
2/ Where we are:
✅ NAC → feasible, active; pathological response = surrogate of survival
✅ POUT → durable DFS benefit emerging OS signal
❌ Neoadjuvant IO mono (PURE-02) → limited
⚠️ Chemo-IO (iNDUCT) → feasible, didn’t meet 1º endpoints
❌ Adjuvant IO → no clear benefit
1
89
3/ Where we’re going:
🔬 ctDNA & utDNA → risk stratification MRD
🧠 Predictive models → reduce overtreatment
📊 Ongoing trials: URANUS, iNDUCT-2, NCT04628767
UTUC-specific prospective trials are no longer optional — they’re urgent.
1
1
196
1/7 📄 New in Urologic Oncology — a systematic review & meta-analysis of 77 studies and >30,000 patients undergoing radical cystectomy (RC) for non-metastatic bladder cancer.
🔗 kwnsfk27.r.eu-west-1.awstrac…
1
1
149
6/7 🩺 Clinical implication: candidate selection for adjuvant therapy and surveillance intensity should integrate these factors — beyond pT/pN alone.
1
37
7/7 ⚠️ Heterogeneous RFS definitions remain a key limitation of the field and a priority for standardization.
#BladderCancer #UroOnc #RadicalCystectomy #SurvivalAnalysis
43